摘要
目的 :对比齐拉西酮与利培酮治疗女性首发精神分裂症的疗效与安全性。方法 :选择2014年1月~2018年1月我院收治的女性首发精神分裂症患者150例,以随机数字表将其分为对照组与研究组,每组各75例。对照组口服利培酮治疗,研究组口服齐拉西酮治疗。采用阳性与阴性症状量表(PANSS)量表评价两组患者的临床疗效、治疗前与治疗8w时PANSS评分的变化,以及治疗期间的不良反应。结果 :研究组治疗的总有效率为78.67%,与对照组76.00%对比差异无统计学意义。治疗8w时研究阳性症状、阴性症状与一般精神病理评分低于治疗前,其中研究阴性症状评分低于对照组,两组阳性症状、与一般精神病理评分对比差异无统计学意义。研究组泌乳、体质量增加、月经改变的发生率0.00%、2.67%、1.33%,低于对照组9.33%、10.67%、10.67%。结论 :齐拉西酮与利培酮治疗女性首发精神分裂症的疗效相当,但齐拉西酮对患者阴性症状的改善效果更为理想,且不会导致内分泌系统变化,适于临床推广。
Objective To compare the efficacy and safety of ziprasidone and risperidone in the treatment of female firstepisode schizophrenia.Methods 150 cases of female first-episode schizophrenic patients treated in our hospital in January2014~2018 January were divided into a control group and a study group with a random number table,with 75 cases in each group.The control group was treated with risperidone and the study group was treated with ziprasidone.PANSS scale was used to evaluate the clinical efficacy of two groups of patients,the changes of PANSS scores before treatment and 8 W treatment,and the adverse reactions during treatment.Results The total effective rate of the study group was 78.67%,which was not significantly different from that of the control group 76%.In the treatment of 8 W,the positive symptoms,negative symptoms and general psychopathology scores were lower than those before treatment,and the negative symptom score of the study was lower than that of the control group,and there was no significant difference between the two groups of positive symptoms and the general psychopathology score.The incidence of lactation,body weight gain and menstrual change in the study group were 0%,2.67%and 1.33%,lower than those in the control group 9.33%,10.67%and 10.67%.Conclusion The efficacy of ziprasidone and risperidone in the treatment of female first-episode schizophrenia is equivalent,but the effect of ziprasidone is more ideal for the improvement of the negative symptoms,and it will not lead to the changes of the endocrine system and is suitable for clinical application.
作者
廖东升
郭应丽
阿怀红
王鑫
沈君
Liao Dong-sheng;Guo Ying-li;A Huai-hong;Wang Xin;Shen Jun(Department of Schizophrenia,Third People’s Hospital of Qinghai Province,Xining 810007,China)
出处
《湖南师范大学学报（医学版）》
2019年第3期106-108,共3页
Journal of Hunan Normal University(Medical Sciences)
关键词
齐拉西酮
利培酮
女性
首发精神分裂症
疗效
安全性
ziprasidone
risperidone
female
first-episode schizophrenia
efficacy
safety
